Can fexofenadine and montelukast be safely added to a patient’s post‑myocardial infarction (MI) and percutaneous coronary intervention (PCI) regimen who now has fever and sore throat?

Can Fexofenadine and Montelukast Be Safely Added to Post-MI/PCI Cardiac Medications?

Yes, both fexofenadine and montelukast can be safely added to standard post-MI/PCI cardiac medications, as neither has significant drug interactions with antiplatelet agents, anticoagulants, or other cardiac therapies. However, the fever and sore throat warrant immediate clinical evaluation to rule out infection or post-MI complications before treating symptomatically.

Critical First Step: Evaluate the Fever and Sore Throat

Before adding any symptomatic treatment, you must determine the cause of fever and sore throat in this post-MI/PCI patient:

• Post-MI pericarditis typically occurs 1-3 days after transmural MI with pleuritic chest pain and fever 1
• Dressler syndrome (late pericarditis) can occur weeks after MI with fever, chest pain, and effusions 2
• Infectious pharyngitis requiring antibiotics
• Post-procedural fever which occurs in approximately 25% of STEMI patients after PCI and is associated with worse outcomes 3

Key diagnostic criteria for post-MI pericarditis 1:

• Pleuritic chest pain
• Pericardial friction rub
• ECG changes (PR depression, diffuse ST elevation)
• New or enlarging pericardial effusion

Safety of Fexofenadine in Post-MI/PCI Patients

Fexofenadine has no contraindications or interactions with cardiac medications and can be safely used 4:

• No cardiovascular contraindications listed in FDA labeling
• No drug interactions with aspirin, P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor), beta-blockers, ACE inhibitors, or statins
• Dosing: 60 mg twice daily or 180 mg once daily for allergic rhinitis 4
• Common adverse effects: Headache (10.6%), viral infection (2.5%), minimal drowsiness (1.3%) 4

Important caveat: Fexofenadine is renally excreted, so use caution if the patient has renal impairment 4

Safety of Montelukast in Post-MI/PCI Patients

Montelukast not only appears safe but may have cardioprotective benefits in post-MI patients 5, 6, 7:

Evidence Supporting Use:

• Reduces inflammatory markers: In a randomized controlled trial of NSTEMI patients, montelukast 10 mg twice daily significantly reduced hs-CRP and IL-6 more than placebo after 30 days (P=0.004 for both) 7
• Improves cardiac remodeling: In animal models, montelukast reduced infarct size, prevented wall thinning, improved ejection fraction, and reduced cardiomyocyte hypertrophy after MI 5
• Secondary prevention potential: A nationwide cohort study showed montelukast use was associated with lower risk of recurrent stroke (HR 0.62,95% CI 0.38-0.99) and recurrent MI in males (HR 0.65,95% CI 0.43-0.99) 6

Safety Considerations:

• Standard dosing: 10 mg once daily for allergic rhinitis/asthma 8
• Neuropsychiatric effects: Be aware of potential anxiety, depression, sleep disturbances, particularly in younger patients 9, 10. Monitor mental health symptoms closely
• No cardiac drug interactions: No documented interactions with antiplatelet agents or other cardiac medications

Standard Post-MI/PCI Medications That Must Continue

Your patient should be on the following regimen per current guidelines 11, 1, 12:

Antiplatelet therapy:

• Aspirin 75-100 mg daily indefinitely 11, 12
• P2Y12 inhibitor (clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily) for at least 12 months 1, 12

Other cardiac medications:

• Beta-blocker (indefinitely) 13
• ACE inhibitor or ARB (especially if LVEF ≤40%, hypertension, or diabetes) 13
• High-intensity statin 11

Clinical Algorithm

1. Immediately assess fever etiology:

   • Check for pericardial friction rub, pleuritic chest pain
   • Review ECG for pericarditis changes
   • Consider echocardiogram if pericarditis suspected
   • Throat examination for pharyngitis

2. If infectious pharyngitis: Treat with appropriate antibiotics; hold off on antihistamines until diagnosis clear

3. If post-MI pericarditis 1:

   • Acetaminophen for symptomatic relief
   • High-dose aspirin 500-1000 mg every 6-8 hours (already on low-dose aspirin for cardiac indication)
   • Consider colchicine 0.5-0.6 mg once or twice daily for 3 months
   • Avoid NSAIDs (except aspirin) due to impaired myocardial healing risk

4. If allergic rhinitis/upper respiratory symptoms without infection:

   • Add fexofenadine 180 mg once daily
   • Consider adding montelukast 10 mg once daily (may provide additional anti-inflammatory benefit)
   • Continue all cardiac medications unchanged

Key Pitfalls to Avoid

• Do not use NSAIDs (other than aspirin) for fever/pain in post-MI patients—risk of impaired healing and recurrent MI 1
• Do not use glucocorticoids for post-MI pericarditis unless absolutely necessary—increased rupture risk 1
• Do not assume fever is benign—post-procedural fever after PCI is associated with higher 1-year MACE rates (11.0% vs 4.7%, p=0.010) 3
• Monitor for neuropsychiatric symptoms if using montelukast, especially mood changes or sleep disturbances 9, 10

Bottom line: Both medications can be safely added, but first rule out serious post-MI complications or infection causing the fever and sore throat.